

# **URETHRAL CARCINOMA**

# **General Overview**

- Very rare
- Presentation: mostly bloody discharge, bladder outlet obstruction, pain, visible mass
- Histology: urothelial carcinoma (+- 60%), squamous (+- 20%) or adenocarcinoma (+- 14%, but >40% in woman)

# Diagnostic work up and staging

- Clinical examination of meatus and inguinal lymph nodes
- Urethrocystoscopy with biopsy
- CT urography
- CT Tx-abdomen
- Pelvic MRI

Male penile urethra and female urethraNx: LN cannot be assessedM0: No distant M+Tx: Primary tumor cannot be assessedN0: No regional LNM1: Distant M+T0: No evidence of primary tumorN1: Single regional LNTa: Noninvasive papillary carcinomaN2: Multiple regional LNTis: Carcinoma in situReg LN:T1: Invasion subepithelial connective tissueReg LN:T2: Invasion corpus spongiosum, periurethral muscle- Proximal 1/3 of female urethra and posterior male urethra: posterior male urethra: pelvicT3: Invasion corpus cavernosum, anterior vagina- Distal 2/3 of female urethra: pelvicT4: Tumor invades other adjacent organs (invasion of the bladder)- Distal 2/3 of female urethra and anterior male urethra and anterior male urethra: inguinal and pelvicT0: No evidence of primary tumoringuinal and pelvicT3: Noninvasive papillary carcinomainguinal and pelvic
T0: No evidence of primary tumor Ta: Noninvasive papillary carcinoma Tis: Carcinoma in situ T1: Invasion subepithelial connective tissue T2: Invasion corpus spongiosum, periurethral muscle T3: Invasion corpus cavernosum, anterior vagina T4: Tumor invades other adjacent organs (invasion of the bladder) Prostatic urethra Tx: Primary tumor cannot be assessed T0: No evidence of primary tumor Ta: Noninvasive papillary carcinoma Tis: Carcinoma in situ involving the prostatic urethra or periurethral or prostatic ducts  N1: Single regional LN N2: Multiple regional LN  N2: Multiple regional LN  Proximal 1/3 of female urethra and posterior male urethra: pelvic  - Distal 2/3 of female urethra and anterior male urethra: inguinal and pelvic
Ta: Noninvasive papillary carcinoma Tis: Carcinoma in situ  T1: Invasion subepithelial connective tissue T2: Invasion corpus spongiosum, periurethral muscle T3: Invasion corpus cavernosum, anterior vagina T4: Tumor invades other adjacent organs (invasion of the bladder) Prostatic urethra Tx: Primary tumor cannot be assessed T0: No evidence of primary tumor Ta: Noninvasive papillary carcinoma Tis: Carcinoma in situ involving the prostatic urethra or periurethral or prostatic ducts  Reg LN: Proximal 1/3 of female urethra and posterior male urethra:  - Distal 2/3 of female urethra: male urethra: inguinal and pelvic
Tis: Carcinoma in situ  T1: Invasion subepithelial connective tissue T2: Invasion corpus spongiosum, periurethral muscle T3: Invasion corpus cavernosum, anterior vagina T4: Tumor invades other adjacent organs (invasion of the bladder) Prostatic urethra Tx: Primary tumor cannot be assessed T0: No evidence of primary tumor Ta: Noninvasive papillary carcinoma Tis: Carcinoma in situ involving the prostatic urethra or periurethral or prostatic ducts  Reg LN: Proximal 1/3 of female urethra and posterior male urethra: postatic urethra: urethra and anterior male urethra: inguinal and pelvic
T1: Invasion subepithelial connective tissue T2: Invasion corpus spongiosum, periurethral muscle T3: Invasion corpus cavernosum, anterior vagina T4: Tumor invades other adjacent organs (invasion of the bladder) Prostatic urethra Tx: Primary tumor cannot be assessed T0: No evidence of primary tumor Ta: Noninvasive papillary carcinoma Tis: Carcinoma in situ involving the prostatic urethra or periurethral or prostatic ducts  Reg LN: Proximal 1/3 of female urethra and posterior male urethra: Distal 2/3 of female urethra and anterior male urethra: inguinal and pelvic
T2: Invasion corpus spongiosum, periurethral muscle T3: Invasion corpus cavernosum, anterior vagina T4: Tumor invades other adjacent organs (invasion of the bladder) Prostatic urethra Tx: Primary tumor cannot be assessed T0: No evidence of primary tumor Ta: Noninvasive papillary carcinoma Tis: Carcinoma in situ involving the prostatic urethra or periurethral or prostatic ducts  - Proximal 1/3 of female urethra and posterior male urethra: pelvic  - Distal 2/3 of female urethra and anterior male urethra: inguinal and pelvic
muscle T3: Invasion corpus cavernosum, anterior vagina
T3: Invasion corpus cavernosum, anterior vagina  T4: Tumor invades other adjacent organs (invasion of the bladder)  Prostatic urethra  Tx: Primary tumor cannot be assessed T0: No evidence of primary tumor Ta: Noninvasive papillary carcinoma Tis: Carcinoma in situ involving the prostatic urethra or periurethral or prostatic ducts  posterior male urethra: pelvic  Distal 2/3 of female urethra and anterior male urethra: inguinal and pelvic
vagina urethra: pelvic  T4: Tumor invades other adjacent organs - Distal 2/3 of female (invasion of the bladder) urethra and anterior Prostatic urethra male urethra:  Tx: Primary tumor cannot be assessed inguinal and pelvic  T0: No evidence of primary tumor  Ta: Noninvasive papillary carcinoma Tis: Carcinoma in situ involving the prostatic urethra or periurethral or prostatic ducts
T4: Tumor invades other adjacent organs (invasion of the bladder)  Prostatic urethra  Tx: Primary tumor cannot be assessed T0: No evidence of primary tumor Ta: Noninvasive papillary carcinoma Tis: Carcinoma in situ involving the prostatic urethra or periurethral or prostatic ducts  - Distal 2/3 of female urethra and anterior male urethra: inguinal and pelvic
(invasion of the bladder)  Prostatic urethra  Tx: Primary tumor cannot be assessed  T0: No evidence of primary tumor  Ta: Noninvasive papillary carcinoma  Tis: Carcinoma in situ involving the prostatic urethra or periurethral or prostatic ducts
Prostatic urethra male urethra:  Tx: Primary tumor cannot be assessed inguinal and pelvic  T0: No evidence of primary tumor  Ta: Noninvasive papillary carcinoma  Tis: Carcinoma in situ involving the prostatic urethra or periurethral or prostatic ducts
Tx: Primary tumor cannot be assessed inguinal and pelvic T0: No evidence of primary tumor Ta: Noninvasive papillary carcinoma Tis: Carcinoma in situ involving the prostatic urethra or periurethral or prostatic ducts
T0: No evidence of primary tumor Ta: Noninvasive papillary carcinoma Tis: Carcinoma in situ involving the prostatic urethra or periurethral or prostatic ducts
Ta: Noninvasive papillary carcinoma Tis: Carcinoma in situ involving the prostatic urethra or periurethral or prostatic ducts
<b>Tis</b> : Carcinoma in situ involving the prostatic urethra or periurethral or prostatic ducts
urethra or periurethral or prostatic ducts
without stromal invastion
T1: Invasion urethral subepithelial connective
tissue immediately underlying the urothelium
T2: Invasion prostatic stroma surrounding ducts
either by direct extension from the urothelial
surface or invasion prostatic ducts
T3: Invasion periprostatic fat
T4: Invasion other adjacent organs ( bladder wall, rectal wall)
wall, rectal wall)

Update: September 2024



Prognostic stage group	TNM
Ois	Tis N0 M0
0a	Ta N0 M0
1	T1 N0 M0
II	T2 N0 M0
III	T1 N1 M0
	T2 N1 M0
	T3 N0 M0
	T3 N1 M0
IV	T4 N0 M0
	T4 N1 M0
	Any T, N2, M0
	Any T, any N, M1

## **Treatment**

### Localized disease (cTa-2N0)

- Prostatic urethra:
  - o Ta-Tis-T1: repeat TUR + BCG.
    - ➤ If BCG-unresponsive or extensive: consider cystoprostatectomy +/- urethrectomy + lymphadenectomy.
  - o T2: cystoprostatectomy + urethrectomy + lymphadenectomy.
- Non-prostatic urethra: urethrectomy (partial or complete)

### Locally advanced (cT3-4 or N1-2):

- Urothelial histology: neo-adjuvant chemo (cis-gem/dd-MVAC) + urethrectomy (incl lymphadenectomy for N1-2)
- Squamous histology:
  - o concurrent chemoradiotherapy
  - o alternative: urethrectomy (incl lymphadenectomy for N1-2) + adjuvant radiotherapy

Local relapse: Salvage radiotherapy or surgery

**Metastatic disease:** Systemic therapy depending on histology. For urothelial carcinoma, follow MIBC guidelines

Update: September 2024